Open-Label Extension Study to Evaluate the Long Term Safety and Efficacy of ESK-001 in Plaque Psoriasis
A Study to Evaluate the Long Term Safety and Efficacy of ESK-001 in Patients With Plaque Psoriasis
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Alberta
-
Edmonton, Alberta, Canada, T6G 1C3
- Investigator Site #2001
-
-
British Columbia
-
Surrey, British Columbia, Canada, V3V 0C6
- Investigator Site # 2008
-
-
Manitoba
-
Winnipeg, Manitoba, Canada, R3M 3Z4
- Investigator Site #2003
-
-
Ontario
-
London, Ontario, Canada, N6H 5L5
- Investigator Site #2006
-
Mississauga, Ontario, Canada, L4Y 4C5
- Investigator Site # 2004
-
North Bay, Ontario, Canada, PiB 3Z7
- Investigator Site # 2007
-
Oakville, Ontario, Canada, L6J 7W5
- Investigator Site #2005
-
Toronto, Ontario, Canada, M3H 5Y8
- Investigator Site #2009
-
Waterloo, Ontario, Canada, N2J 1C4
- Investigator Site # 2002
-
-
Quebec
-
Québec, Quebec, Canada, G1V 4X7
- Investigator Site # 2010
-
-
-
-
Alabama
-
Birmingham, Alabama, United States, 35205
- Investigator Site # 1029
-
-
Arizona
-
Phoenix, Arizona, United States, 85032
- Investigator Site #1001
-
-
Arkansas
-
Rogers, Arkansas, United States, 72758
- Investigator Site # 1023
-
-
California
-
Encinitas, California, United States, 92024
- Investigator Site #1021
-
Los Angeles, California, United States, 90045
- Investigator Site #1018
-
Santa Monica, California, United States, 90404
- Investigator Site #1007
-
Sherman Oaks, California, United States, 91403
- Investigator Site #1002
-
-
Florida
-
Fort Lauderdale, Florida, United States, 33308
- Investigator site # 1030
-
Hialeah, Florida, United States, 33012
- Investigator Site #1025
-
Miami, Florida, United States, 33175
- Investigator site # 1028
-
Tampa, Florida, United States, 33614
- Investigator Site # 1013
-
-
Georgia
-
Macon, Georgia, United States, 31217
- Investigator Site #1035
-
Sandy Springs, Georgia, United States, 30328
- Investigator Site #1043
-
-
Illinois
-
Rolling Meadows, Illinois, United States, 60008
- Investigator Site #1005
-
-
Indiana
-
Columbus, Indiana, United States, 47201
- Investigator Site # 1011
-
South Bend, Indiana, United States, 46617
- Investigator Site #1027
-
-
Kansas
-
Overland Park, Kansas, United States, 66210
- Investigator SIte#1036
-
-
Kentucky
-
Owensboro, Kentucky, United States, 42301
- Investigator Site #1017
-
-
Maryland
-
Rockville, Maryland, United States, 20850
- Investigator Site #1026
-
-
Michigan
-
Clarkston, Michigan, United States, 48346
- Investigator Site #1010
-
-
Minnesota
-
New Brighton, Minnesota, United States, 55112
- Investigator Site #1031
-
-
Oklahoma
-
Norman, Oklahoma, United States, 73071
- Investigator Site #1033
-
-
Oregon
-
Portland, Oregon, United States, 97223
- Investigator Site #1019
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19103
- Investigator Site #1022
-
-
South Dakota
-
Rapid City, South Dakota, United States, 57702
- Investigator Site # 1012
-
-
Texas
-
Houston, Texas, United States, 77056
- Investigator Site #1015
-
San Antonio, Texas, United States, 78213
- Investigator Site # 1006
-
-
Utah
-
South Jordan, Utah, United States, 84095
- Investigator Site # 1041
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Must have completed a prior ESK-001 study
- Men and Women must use highly effective methods of contraception for the entirety of the study
Exclusion Criteria:
- Pregnancy
- Received a prohibited concomitant medication
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: envudeucitinib Dose Level 1
envudeucitinib administered as an oral tablet
|
Oral tablet
|
|
Experimental: envudeucitinib Dose Level 2
envudeucitinib administered as an oral tablet
|
Oral tablet
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
To assess the safety and tolerability of long-term ESK-001 treatment
Time Frame: Approximately 3 years
|
Incidence of treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs)
|
Approximately 3 years
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
To assess the long-term efficacy of ESK-001
Time Frame: Approximately 3 years
|
Change from baseline in Psoriasis Area and Severity Index (PASI) over time
|
Approximately 3 years
|
|
To assess the change in quality of life (QoL) with long-term ESK-001 administration
Time Frame: Approximately 3 years
|
Change from baseline in Dermatology Life Quality Index (DLQI) over time
|
Approximately 3 years
|
|
To assess the pharmacokinetics (PK) of ESK-001 (ctrough)
Time Frame: 2 years
|
Plasma concentrations and PK parameters including steady-state trough observed plasma concentration (Ctrough) for ESK-001
|
2 years
|
Collaborators and Investigators
Sponsor
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- ESK-001-007
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.